Navigation Links
Intensive statin therapy may partially reverse plaque build-up in arteries

A study presented today at the American College of Cardiology's 55th Annual Scientific Session demonstrates, for the first time, that very intensive cholesterol lowering with a statin drug can regress (partially reverse) the buildup of plaque in the coronary arteries.

This finding has never before been observed in a study using statin drugs, the most commonly used cholesterol lowering treatment. Previous research had indicated that intensive statin therapy could prevent the progression of coronary atherosclerosis, or arterial plaque build-up, but not actually reduce disease burden. ACC.06 is the premier cardiovascular medical meeting, bringing together more than 30,000 cardiologists to further breakthroughs in cardiovascular medicine.

The intense statin therapy used in this study resulted in significant regression of atherosclerosis as measured by intravascular ultrasound (IVUS), a technique in which a tiny ultrasound probe is inserted into the coronary arteries to measure plaque. The study showed that regression occurred for all three pre-specified IVUS measures of disease burden. The mean baseline LDL cholesterol of 130.4 mg/dL dropped to 60.8 mg/dL in the study patients, an reduction of 53.2 percent. This is the largest reduction in cholesterol ever observed in a major statin outcome trial. Mean HDL cholesterol (43.1 mg/dL at baseline) increased to 49.0 mg/dL, a 14.7 percent increase, which was also unprecedented. The arterial plaque overall was reduced by 6.8 to 9.1% for the various measures of disease burden.

This study was known by the acronym of ASTEROID (A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden [ASTEROID] Trial). The trial was conducted at 53 community and tertiary care centers in the United States, Canada, Europe, and Australia. A total of 507 patients had baseline intravascular ultrasound (IVUS) examination and received 40 mg daily of rosuvastatin (brand name Cr
'"/>

Source:American College of Cardiology


Page: 1 2

Related biology news :

1. President Bushs cut to AIDS prevention in Africa would be devastating
2. Novel targets found for the development of drugs to complement, or replace, statins
3. Quick identification needed to save Floridas citrus industry from devastating disease
4. Patients can report statins adverse effects on new web site
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Columbia research lifts major hurdle to gene therapy for cancer
7. Combination therapy boosts effectiveness of telomere-directed cancer cell death
8. Gene therapy converts dead bone graft to new, living tissue
9. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
10. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
11. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
Post Your Comments:
(Date:7/28/2014)... Wyss Institute for Biologically Inspired Engineering at Harvard ... will be commercialized by a newly formed private ... and personalized medicine products. The announcement ... of Technology Development (OTD) and the start-up Emulate ... automated human Organs-on-Chips platform. , "This is ...
(Date:7/27/2014)... wiped them out if it had taken place slightly ... fresh study using up-to-date fossil records and improved analytical ... of the prehistoric creatures, demise, some 66 million years ... years before a 10km-wide asteroid struck what is now ... volcanic activity, changing sea levels and varying temperatures. ...
(Date:7/27/2014)... studies have shown the potential for global climate change ... the most part, ignored the interactions between increasing temperature ... known to damage crops. , A new study involving ... quite significant, suggesting that policymakers need to take both ... security. , The study looked in detail at global ...
Breaking Biology News(10 mins):Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 2Wyss Institute's technology translation engine launches 'Organs-on-Chips' company 3Dinosaurs fell victim to perfect storm of events, study shows 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3
... the most rapidly increasing food production system worldwide through ... 2009 issue of BioScience . The assessment, by ... Ann Arbor, notes that despite well-publicized concerns about ... practiced well, be no more damaging to biodiversity than ...
... has worked out how some newly discovered light sensors ... brain. The report appears online this week in ... small number of nerve cells in the retina that ... retinarods and conesmelanopsin-containing cells are not used for seeing ...
... DNA modification in lung cancer, a team of international researchers ... They say that "silencing" of a single gene in lung ... cells, contributing to cancer development and progression. In the ... journal of the American Association for Cancer Research, they also ...
Cached Biology News:Aquaculture's growth seen as continuing 2Bright lights, not-so-big pupils 2Bright lights, not-so-big pupils 3In lung cancer, silencing one crucial gene disrupts normal functioning of genome 2In lung cancer, silencing one crucial gene disrupts normal functioning of genome 3
(Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
(Date:7/28/2014)... -   JOLT , a leading technology accelerator, announced ... growing portfolio of startups. Next-level tech and boundary-pushing innovation ... JOLT accelerator, and Cohort four is no exception, with ... Since its launch in July 2012, JOLT has produced ... Now at 23 investments, JOLT,s portfolio has an overall ...
(Date:7/28/2014)... 28, 2014  David Hardison, Ph.D., vice president ... , has been elected chairman of the board ... non-profit working to establish common protocols around the ... relates to electronic health records. ... collaborating with organizations across the research and health ...
(Date:7/28/2014)... , July 28, 2014   Propeller Health ... disease, announced the hire of Brad Towle ... will be responsible for driving the company,s sales growth, ... experience in healthcare, and specifically his past role in ... to the company at this pivotal time in the ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... , , ... 8 /PRNewswire-Asia/ -- The Jiangsu Government,s,Science and Technology Department ... Achievements Transformational Grant - to support the,research and development ... grant recipient and administrator, Shenzhen Beike,Biotechnology Co., Ltd. ( ...
... , NORTH BILLERICA, Mass., Dec. 29 ... of instruments for measuring cellular bioenergetics, announced that TheScientist ... 2009 Top Ten Innovation. , A panel of scientific experts ... the first instrument to measure the two energy pathways of ...
... , ORLANDO, Fla., Dec. 28 ... a leading consumer genomics and biotechnology company ( www.genelinkbio.com ), ... as its interim Chief Executive Officer, effective December 28, 2009. ... with more than 25 years of experience building high performance ...
Cached Biology Technology:Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials 2Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials 3Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials 4TheScientist Awards Seahorse XF96 Analyzer a Top Ten Innovation for 2009 2David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 2David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 3David L. Macdonald Appointed CEO of GeneLink BioSciences, Inc. 4
Mouse Aminopeptidase P2/XPNPEP2 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
Request Info...
Request Info...
Size & Applications: 100 ul (2 mM). Recommend to use at 1000X dilutions for cell culture (e.g. Add 1 ul to 1 ml of culture medium.) Storage Temp.: -20C Shelf Life: 6-12 month...
Biology Products: